therapeutics

Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference

TORONTO, Aug. 7 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI , TSX:TTH) today announced that Dr. Tony Cruz, Chairman and Chief Executive Officer, will present at the upcoming Canaccord Adams 29th Annual Global Growth Conference. Dr. Cruz's pr...

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced unaudited financial results for the three months ended June 30, 2009. Three Months Ended June 30, 2...

United Therapeutics Corporation Reports Second Quarter 2009 Financial Results

SILVER SPRING, Md., July 31 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ) today announced its results of operations for the quarter ended June 30, 2009. Total revenues for the second quarter of 2009 were $84.0 million, up from $68.6 m...

Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe

SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it was notified by the European Medicines Agency ("EMEA") that pixantrone is eligible to be submitted for a Marketing Authorization Application ("MAA") through...

Orexigen(R) Therapeutics Prices Public Offering of Common Stock

SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price of $7.50 per share. Net proceeds, after estimated underwriting discounts and c...

Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Orexigen...

Echo Therapeutics to Present at Jessup & Lamont 2009 Growth Stock Conference

FRANKLIN, Mass., July 20 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelud...

The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics today announced a partnership to accelerate LLS's pipeline of research projects entering late pre-clinical development. The collaboration will beg...

Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product

CARY, N.C., July 15 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it has submi...

InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer

LOS ALTOS, Calif., July 13 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Geoffrey M. Parker has joined InteKrin as Chief Business Officer. Most recently, Mr. Parker served as a Managing Director and Partner in the Investment Banking Division of Goldman, Sachs &...

therapeutics in Medical Technology

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the Contrave program on Monday, July 20, 2009 be...

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

PITTSBURGH, July 16 /PRNewswire/ -- Cognition Therapeutics Inc., a Pittsburgh-based drug discovery company developing small molecule disease-modifying treatments for Alzheimer's, has closed on a $1.21M Series A financing. The round was led by Ogden CAP, LLC of New York City and inc...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo act...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

- FDA Agreement Reached on Phase 3 Study Design, Primary Endpoint and Histological Methodology - CRANBURY, N.J., June 22 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal...

InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapi...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

Small Molecule Stem Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic Malignancy LA JOLLA, Calif., May 27 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem C...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) A...

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone WALTHAM, Mass., May 11 /PRNewswire/ -- Logical Therapeutics, Inc (Logical), a biotechnology company focused on the development of products that treat diseases associated w...

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of s...

More>>

therapeutics in Medical Products

ACT PLUS Automated Coagulation Timer System

Description:...rmed. The ability to externally transfer or save data to a floppy disk enhances the systems versatility. Manufactured by the Medtronic Biologic therapeutics and Diagnostics business, the ACT Plus System combines a trusted standard in precise clot detection technology with state-of-the-art user enhancements...
Company:Medtronic Inc.

Avanar FX

Description:... Compatible with the Volcano therapeutics Trak Back II Disposable Catheter Pullback Device and the Volcano therapeutics In-Vision Imaging System....
Company:Volcano Therapeutics, Inc.

The Washington Manual® Cardiology Subspecialty Consult

Features:...ont-lines practicality as the world-famous The Washington Manual of Medical therapeutics Covers both inpatient and outpatient approaches with the same front-lines practicality as the world-famous The Washington Manual of Medical therapeutics Includes sections on Imaging and diagnostic testing modalities, Managemen...
Company:Skyscape, Inc.

therapeutics in Biological News

Amarna Therapeutics B.V. and TNO announce SVac research and development partnership

Leiden, The Netherlands, June 09, 2009 / b3c newswire / - Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna’s viral gene...

NIH announces new program to develop therapeutics for rare and neglected diseases

The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases Program, or TRND. The progr...

Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB

LONDON and SAN DIEGO, April 2, 2009 University College London Business PLC (UCLB) and Ocera Therapeutics Inc., a privately held biopharmaceutical company, announced the signing of an exclusive worldwide licensing agreement for UCL-L1V and all assets and technologies related to the compound for th...

Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis

HAWTHORNE, N.Y., February 2, 2009 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) on January 30, 2009 for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multi...

A novel target for therapeutics against Staph infection

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a fi...

Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration

Palo Alto, CA and New York, NY, October 30, 2008 Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill...

Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery

CAMBRIDGE, MA [October 1, 2008] Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it published a new review article on the growing body of sirtuin research and its potential to treat diseases ...

Michael J. Fox Foundation PD Therapeutics Conference

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will host its second annual PD Therapeutics Conference on Monday, September 15, in Chicago. Chaired by Jeffrey Kordower, PhD, Director, Research Center for Brain Repair and Jean-Schweppe Armour Professor of Neurological Sciences at ...

Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration

Mechelen, Belgium and Bethesda, Maryland, USA; 29 November 2007 Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, announced today a new collaboration aimed at discovering new treatments for cys...

Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics

New Rochelle, NY, May 29, 2009Continuous Glucose Monitoring (CGM) devices represent a critical step toward achieving automated glucose measurement, offering people with diabetes a promising new tool for maintaining optimal glucose control. A comprehensive review of this rapidly changing field, fea...

therapeutics in Biological Technology

Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for the second quarter and six months ended June 30, 2009. "The second quarter of 2009 was a transforming quarter for the Co...

The Breast Cancer Therapeutics Market in Australia

SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the total number of breast cance...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

CRANBURY, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced financial results for the second quarter 2009. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced...

Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 29th Annual Canaccord Adams Global Growth Conference. The details are as fol...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York City on Wednesday, August 5, 2009 at 1:45 p.m. ...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Fron...

Cornerstone Therapeutics Announces Closing of Chiesi Transaction

CARY, N.C., July 30 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it has close...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date

CRANBURY, N.J., July 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) will announce second quarter 2009 financial results after the regular close of markets on Wednesday, August 5, 2009. The results announcement will be followed by a live conference call and webcas...

PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2

SOUTH PLAINFIELD, N.J., July 27 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors....

Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters

SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announced that its underwriters fully exercised their overallotment option to purchase an additional 1,500,000 shares of its common stock in connection with its previously announced public of...

therapeutics in Biological Products

SpliceArray Service from ExonHit Therapeutics Inc.

Description: SpliceArray is a new generation of microarrays to detect alternative splicing. SpliceArray Service enables you to rapidly elucidate alternatively spliced events in gene families known to be relevant for drug discovery. The service combines ExonHits proprietary splice variant content, patented pro...
Company:ExonHit Therapeutics Inc.

Microarray expression profiling service from ExonHit Therapeutics Inc.

Description: SpliceArray Services is a microarray service provider that supports industrial and academic researchers. We are a Certified Servive Provider of Agilent, and we provide expression profiling services on all Agilent catalogue arrays. Gene expression reports are delivered via CD....
Company:ExonHit Therapeutics Inc.

Ion Channel SpliceArray Service from ExonHit Therapeutics Inc.

Description: The binding specificity and signaling of the members of the GPCR family are known to be modified by alternative splicing--which has important implications for drug research. With GPCR SpliceArrays you can perform a classical expression profiling and at the same time detect the different alternative...
Company:ExonHit Therapeutics Inc.

Custom Splice Arrays from ExonHit Therapeutics Inc.

Description: Through its SpliceArray service, ExonHit can design custom microarrays to detect alternative splicing events starting with your gene list. Proprietary algorithms are used to identify splice events and design microarray probes from high quality, spliced cDNAs aligned to the human genome. Each splic...
Company:ExonHit Therapeutics Inc.

Apoptosis Pathway SpliceArrays from ExonHit Therapeutics Inc.

Description: Alternative Splicing plays an important role in the regulation of signaling pathways involved in apoptosis and cell death. Splice variants have been reported that affect both the activation and inhibition of defined apoptotic pathways. With Apoptosis and Cell Death SpliceArrays you can perform a c...
Company:ExonHit Therapeutics Inc.

GPCR SpliceArray Service from ExonHit Therapeutics Inc.

Description: The binding specificity and signaling of the members of the GPCR family are known to be modified by alternative splicing--which has important implications for drug research. With GPCR SpliceArrays you can perform a classical expression profiling and at the same time detect the different alternative...
Company:ExonHit Therapeutics Inc.

More>>

therapeutics in Biological Definition

Systems biology

... Many predictions concerning the impact of genomics on health care have been presented. For example, the development of novel therapeutics and the introduction of personalised treatments are conjectured and in fact are now becoming a reality as a small number of forward-thinking biotechno...

therapeutics in Biological Dictionary

Ribozyme

...implications for ... and siRNA-mediated gene silencing in vivo with ribozyme -based reporters. ... Biotechnology company focused on developing therapeutics based on RNA interference (RNAi) technology. Ribozyme - Norwegian hard rock band. Ribozyme - Scapegoat chronicles ...

Proteome

... | Partners ... Copyright 2009 Proteome Software ... Enhancing Protein therapeutics Through Selective Modification ... Advanced Proteome therapeutics Corporation Announces Advances in Technology in ... Structural genomics...

Peptides

.... PeptACE? Peptides 90C by Natural Factors - available now at WebVitamins.com for only $29.38. Free Shipping on U.S. orders over $99 Peptide therapeutics has once again become the focus of innovative drug development. As potential therapeutics, peptides offer several advantages over small ... ...

Oligonucleotide

...Inc., is. ... and development of oligonucleotide therapeutics (RNAi, CpG, ... © Oligonucleotide therapeutics Society 2009 ... Online Shopping at SpotCost.com - New and used books like Oligonucleotide therapeutics First Annual Meetingof the Oligonucleotide ...

Isozyme

... 2 An example of an isozyme . 3 Distinguishing isozymes ... Development of new isozyme specific therapeutics - Fatty Acid Dioxygenases and ... isozyme ( ) n. An isoenzyme. [ ISO– + (EN)ZYME .] isozymic i ' sozy ' mic adj. ... What is the difference betwe...

Epigenesis

...ienschein (Stanford Encyclopedia of Philosophy) ... Retrieved from "http://en.wikipedia.org /wiki/ Epigenesis " ... Produces molecular therapeutics for respiratory diseases. Epigenesis and Preformation are two persistent ways of describing and seeking to ... Nature or nurture, epigenesis or...

Electroporation

...n , cells are also grown to mid-log phase but are then washed ... Cyto Pulse is a biotechnology company devoted to the pursuit of DNA vaccine therapeutics and delivery systems, ... mechanism of electroporation is not ... The world leader in the field of electroporation and transfection offering ...

Antisense

...nary with audio pronunciations, thesaurus, Word of the Day, and word games. Conclusion: The era of respirable antisense oligonucleotide (RASON) therapeutics was introduced in 1997 with the publication of preclinical data on a 21-mer ... The antisense technique could potentially be used to develop " .....